Abstract
Thyroxine is the tyrosine based hormone produced by the thyroid gland, containing a chiral center in its molecular structure. Synthetic thyroxine is commercially available to treat thyroid dysfunctions, but only a few direct analytical methods to determine its optical purity have been reported. This study attempted to find an optimized liquid chromatographic condition for direct enantiomer separation on crown ether type chiral stationary phase. Among various mobile phases tested, 100% methanol solution containing 10 mM H2SO4 was found to be most appropriate. This chromatographic method was validated and applied to measure the optical purity of six different L-thyroxine products from three domestic pharmaceutical companies and four commercially available D- and L-thyroxine reagents. The chromatographic results showed that every pharmaceutical product had quite high optical purity of above 97% (all but one were higher than 99%) while two of four thyroxine reagents demonstrated relatively higher enantiomer impurity (5–6%).
Similar content being viewed by others
References
Abou-Basha, L. I. and Aboul-Enein, H. Y., Enantiomeric separation and optical purity determination of thyroxine enantiomers in bulk and pharmaceutical formulations. Pharm. Acta Helv., 70, 237–240 (1995).
Aboul-Enein, H. Y., Ali, I., Hyun, M. H., Cho, Y. J., and Jin, J. S., Effect of acidity on the enantiomeric resolution of thyroxine and tocainide by HPLC on a (+)-(18-crown-6)-2,3,11,12-tetracarboxylic acid column. J. Biochem. Biophys. Methods, 54, 407–413 (2002).
Bang, E., Jung, J. W., Lee, W., Lee, D. W., and Lee, W., Chiral recognition of (18-crown-6)-tetracarboxylic acid as a chiral selector determined by NMR spectroscopy. J. Chem. Soc. Perkin Trans. I, 2, 1685–1692 (2001).
Bantle, J., Oppenheimer, J., Schwartz, H., Hunninghake, D., Probstfield, J., and Hanson, R., TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine. Metabolism, 30, 63–66 (1981).
Ekborg-Ott, K. H., Kullman, J. P., Wang, X., Gahm, K., He, L., and Armstrong, D. W., Evaluation of the macrocyclic antibiotic avoparcin as a new chiral selector for HPLC. Chirality, 10, 627–660 (1998).
Francotte, E. and Lindner, W. (Eds.), Chirality in Drug Research. Wiely-VCH, Weinheim, (2006).
Gika, H., Lämmerhofer, M., Papadoyannis, I., and Lindner, W., Direct separation and quantitative analysis of thyroxine and triiodothyronine enantiomers in pharmaceuticals by high-performance liquid chromatography. J. Chromatogr. A, 800, 193–201 (2004).
Hyun, M. H., Jin, J. S., and Lee, W., Liquid chromatographic resolution of racemic amino acids and their derivatives on a new chiral stationary phase based on crown ether. J. Chromatogr. A, 822, 155–161 (1998).
Hyun M. H., Jin, J. S., Koo, H. K., and Lee, W., Liquid chromatographic resolution of racemic amines and amino alcohols on a chiral stationary phase derived from crown ether, J. Chromatogr. A, 837, 75–82 (1999).
Jin, J. Y., Lee, W., and Hyun, M. H., Development of the antipode of the covalently-bonded crown ether type chiral stationary phase for the advantage of the reversal of elution order. J. Liq. Chromatogr. Relat. Technol., 29, 841–848 (2006).
Jin, J. Y., Baek, C. S., and Lee, W., Development of a validated HPLC method for the simultaneous determination of D- and L-thyroxine in human plasma. Bull. Kor. Chem. Soc., 28, 1070–1072 (2007).
Lee, W., Jin, J. Y., and Baek, C. S., Comparison of enantiomer separation on two chiral stationary phases derived from (+)-18-crown-6-2,3,11,12-tetracarboxylic acid of the same chiral selector. Microchem. J., 80, 213–217 (2005).
Thomson Micromedex Healthcare Series. Dextrothyroxine in DRUGDEX® Evaluations. [online] (Updated 09 Feburary 2007) Avaialbe at: http://www.thomsonhc.com [Accessed 21 March 2010]
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jeon, S.H., Kim, M., Han, HK. et al. Direct enantiomer separation of thyroxine in pharmaceuticals using crown ether type chiral stationary phase. Arch. Pharm. Res. 33, 1419–1423 (2010). https://doi.org/10.1007/s12272-010-0916-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-010-0916-8